Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes

British Journal of Dermatology

Volumn 161, Issue 6, 2009, Pages 1232-1238

  Kakurai, M ^a   Demitsu, T ^a   Umemoto, N ^a   Kobayashi, Y ^a,b   Inoue Narita, T ^a   Fujita, N ^c   Ohtsuki, M ^a   Furukawa, Y ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b School of Medicine   (Japan)

^c Imperial Foundation Saiseikai Utsunomiya Hospital   (Japan)

Author keywords

Inflammatory cytokines; Keratinocytes; Psoriasis; Vascular endothelial growth factor; Vasoactive intestinal peptide

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; INFLAMMATORY CELL; KERATINOCYTE; MAST CELL; PRIORITY JOURNAL; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; UPREGULATION;

BLOTTING, WESTERN; CELL LINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; PSORIASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOACTIVE INTESTINAL PEPTIDE;

EID: 72649084666     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09439.x     Document Type: Article

References (37)

1. Braverman IM, Yen A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977 68 : 53 60.
2. Braverman IM, Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 1982 78 : 12 17.
3. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996 271 : 603 606.
4. Detmar M, Brown LF, Claffey KP et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994 180 : 1141 1146.
5. Bhushan M, McLaughlin B, Weiss JB et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999 141 : 1054 1060.
6. Bellinger DL, Lorton D, Brouxhon S et al. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 1996 6 : 5 27.
7. Bjorklund H, Dalsgaard CJ, Jonsson CE et al. Sensory and autonomic innervation of non-hairy and hairy human skin. An immunohistochemical study. Cell Tissue Res 1986 243 : 51 7.
8. Nilsson SFE, Maepea O. Comparison of the vasodilatory effects of vasoactive intestinal polypeptide (VIP) and peptide-HI (PHI) in the rabbit and the cat. Acta Physiol Scand 1987 129 : 17 26.
9. Lowman MA, Benyon RC, Church MK. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol 1988 95 : 121 130.
10. Lotti T, Hautmann G, Panconesi E. Neuropeptides in skin. J Am Acad Dermatol 1995 33 : 482 496.
11. Anand P, Springall DR, Blank MA et al. Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhidrosis. Br J Dermatol 1991 124 : 547 549.
12. Kakurai M, Fujita N, Murata S et al. Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors. J Invest Dermatol 2001 116 : 743 749.
13. Kakurai M, Fujita N, Kiyosawa T et al. Vasoactive intestinal peptide and cytokines enhance stem cell factor production from epidermal keratinocytes DJM-1. J Invest Dermatol 2002 119 : 1183 1188.
14. ++ concentration. J Invest Dermatol 1987 89 : 167 171.
15. Weller EM, Poot M, Hoehn H. Induction of replicative senescence by 5-azacytidine: fundamental cell kinetic differences between human diploid fibroblasts and NIH-3T3 cells. Cell Prolif 1993 26 : 45 54.
16. Shenker BJ, Kushner ME, Tsai CC. Inhibition of fibroblast proliferation by Acionobacillus actinomycetemcomitans. Infect Immun 1982 38 : 986 992.
17. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001 114 : 853 865.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001 29 : e45.
19. Kozlowska U, Blume-Peytavi U, Kodelja V et al. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res 1998 290 : 661 668.
20. Ticher E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. J Biol Chem 1991 266 : 11947 11954.
21. Lachgar S, Charveron M, Gall Y et al. Inhibitory effects of retinoids on vascular endothelial growth factor production by cultured human skin keratinocytes. Dermatology 1999 199 : 25 7.
22. Ballaun C, Weninger W, Uthman A et al. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 1995 104 : 7 10.
23. Poltorak Z, Cohen T, Sivan R et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997 272 : 7151 7158.
24. Lee CB, Socinski MA. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Rev Recent Clin Trials 2007 2 : 117 120.
25. Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007 13 : 5544s 8s.
26. Kuroda K, Sapadin A, Shoji T et al. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001 116 : 713 720.
27. Man XY, Yang XH, Cai SQ et al. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 2008 12 : 649 660.
28. Gille J, Khalik M, Konig V et al. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J Invest Dermatol 1998 111 : 1160 1165.
29. Harada K, Baillie R, Lu S et al. VEGF expression in skin warts. Relevance to angiogenesis and vasodilation. Arch Dermatol Res 2001 293 : 233 238.
30. Naukkarinen A, Harvima I, Paukkonen K et al. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res 1993 285 : 341 346.
31. Chan J, Smoller BR, Raychauduri SP et al. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997 289 : 611 616.
32. Pincelli C, Fantini F, Romualdi P et al. Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol 1992 98 : 421 427.
33. Haegerstrand A, Jonzon B, Dalsgaard CJ et al. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci USA 1989 86 : 5993 5996.
34. Sung KJ, Chang SE, Paik EM et al. Vasoactive intestinal peptide stimulates the proliferation of HaCaT cell via TGF-α. Neuropeptides 1999 33 : 435 446.
35. Eedy DJ, Johnston CF, Shaw C et al. Neuropeptides in psoriasis: an immunocytochemical and radioimmunoassay study. J Invest Dermatol 1991 96 : 434 438.
36. Arican O, Aral M, Sasmaz S et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005 2005 : 273 279.
37. Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993 101 : 701 705.